Related Experiment Video
Updated: May 24, 2026
09:13
Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
Published on: April 6, 2017
Prednisolone exerts exquisite inhibitory properties on platelet functions
Elisabetta Liverani1, Sreemoti Banerjee, Wayne Roberts
1William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London, United Kingdom.
Biochemical Pharmacology
|February 28, 2012
Summary
Prednisolone (Pred) inhibits platelet aggregation, adhesion, and thrombus formation via non-genomic actions. This synthetic glucocorticoid (GC) may offer new therapeutic strategies for vascular and thrombotic diseases.
Area of Science:
- Biochemistry
- Hematology
- Pharmacology
Background:
- Glucocorticoid (GC) receptor alpha (GR) is present on blood platelets.
- Synthetic GC prednisolone (Pred) modulates platelet aggregation via GR activation.
Purpose of the Study:
- Investigate broader effects of Pred on platelet functions.
- Unveil novel non-genomic actions of Pred on platelets.
- Explore Pred's potential in managing vascular and thrombotic diseases.
Main Methods:
- Whole blood assays to assess platelet aggregation and interactions.
- Static and flow assays to evaluate platelet adhesion, spreading, and thrombus formation.
- Analysis of signaling pathways, including cyclic nucleotides and P2Y₁₂ ADP receptor.
Main Results:
- Pred uniquely inhibited platelet aggregation and platelet-monocyte interactions.
- Pred reduced platelet adhesion and spreading on collagen under static conditions.
- Pred inhibited thrombus formation under flow, targeting activation-dependent pathways.
- Pred's effects were independent of cyclic nucleotide signaling, involving P2Y₁₂ ADP receptor regulation.
Conclusions:
- Pred exhibits novel non-genomic actions on platelets, impacting aggregation, adhesion, and thrombus formation.
- Pred's mechanism involves selective regulation of P2Y₁₂ ADP receptor signaling.
- Pred demonstrates potential therapeutic relevance for preventing vascular and thrombotic diseases.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Structure and Function of Platelets
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:20Desensitization and Tachyphylaxis
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Several...
01:25Dose-Response Relationship: Selectivity and Specificity
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...